The progressive production and subsequent accumulation of -amyloid (A ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's Disease (AD). A is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of A culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains. In this review we report the known structural features of amyloid peptides and fibrils, and we give an overview of all small molecules that have been found to interact with A aggregation. Deeper knowledge of the mechanism leading to amyloid fibrils along with their molecular structure and the molecular interactions responsible for activity of small molecules could supply useful information for the design of new AD therapeutic agents.
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia among neurodegenerative diseases in the elderly population, affecting about 25 million people worldwide (2005) . In Western countries it is the fourth common cause of death after heart disease, cancer and stroke. Its incidence and costs are predicted to raise due to increasing life expectancy and average age [1, 2] . Hence it was estimated that the number of affected people will double every 20 years [3] , emphasizing the role of AD as a major health problem that will gain even more ethical and economical relevance in near future. Clinical manifestations of this progressive and irreversible dementia are memory loss and cognitive decline [4, 5, 6] . At the microscopic level, the characteristic lesions in Alzheimer's disease are extracellular senile or neuritic plaques, constituted by deposits of -amyloid (A ) peptide, and by intraneuronal fibrillary tangles in the medial temporal lobe structures and cortical areas of the brain, constituted by abnormally hyperphosphorylated protein tau, together with degeneration of the neurons and synapses.
The mechanisms underlying AD are not yet completely clear but genetic, pathological and biochemical clues suggest that the progressive production and subsequent accumulation of the -amyloid (A ), a proteolytic fragment of the membrane-associated Amyloid Precursor Protein (APP), play a central role. A peptide, the major component of neuritic plaque, is formed in abnormal amounts by an aberrant cleavage of Amyloid Precursor Protein (APP), a transmembrane glycoprotein (100-130 kDa) whose primary function is not known although it is implicated in neural plasticity and synapse formation of neurons. The major physiological route of APP processing in neurons is carried out by -secretase and -secretase to produce P3 protein. Instead, in AD an amyloidogenic pathway is boosted with the cleavage of APP by *Address correspondence to this author at the Department of Biotechnology and Biosciences, University of Milano Bicocca, piazza della Scienza 2, 20126, Milano, Italy; Tel: +39 02 6448 2152; Fax: +39 02 6448 2169; E-mail: francesco.nicotra@unimib.it -secretase followed by -secretase, to produce A peptides with a number of amino acid residues ranging between 39 and 42. The predominant ones are A 1-40 (90%) and A 1-42 (10%) as determined by biochemical studies on cell lysates and brains. In the brain, cells release this peptide in a soluble form that, under normal circumstances, is cleared. However, under abnormal conditions rendering more APP prone to -secretase cleavage, the A clearance mechanism in the process is overloaded. This eventually leads to accumulation of A that progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. The aggregation and accumulation of A culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains.
STRUCTURAL FEATURES
The toxic effects manifested in AD are thought to arise as a result of conformational changes in A monomers from predominantly -helical to a mixture of folding intermediates rich in -structures that lead to monomer aggregation and consequently fibril formation. In the last few years, it has been shown that soluble oligomers might be more important pathologically than fibrillar-amyloid deposits [7] . This amyloid forming tendency is highly modulated by the amino acid composition [8] .
The Sequence of A 1-42 is the Following

NH 2 -DEAFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA-COOH
The A 1-42 sequence is divided into two regions. Residues 1-28 make up a relatively hydrophilic domain that in APP is extracellular. The C-terminal residue 28-42 represents an hydrophobic domain associated with the cell membrane in APP. A 1-40 and A 1-42 peptides are mainly present as random coil in aqueous solution, but contain some secondary structure elements: a poly-proline II helix (PII) in the N-terminus, and two -strands in the central part and in the C-terminus [9] . The dynamics of monomeric A 1-40 in aqueous solution was studied by Danielsson et al. [10] by heteronuclear nuclear magnetic resonance experiments.
The soluble monomeric peptide has a high tendency to form A oligomers, which eventually produce A fibrils [11] . At pH values comprised between 4 and 7, it rapidly precipitates giving rise to an oligomeric -sheet structure. Although A 1-40 and A 1-42 possess identical amino acid sequence, numerous in vitro and in vivo studies indicate that both peptides have different aggregation and deposition properties. In particular, A 1-42 aggregates much faster than A 1-40 in vitro and is more toxic than A 1-40. In 2008, Shen et al [12] performed parallel molecular dynamics (MD) simulations on A 1-40 and A 1-42 to investigate their thermal unfolding processes with the aim to explore the physical basis underlying the different dynamic behaviors of both A peptides.
NMR investigations on small A fragments [13] and A -(1-40)Met35ox suggest that in aqueous solution A peptides can be described as random coils, with only a small population of local nonrandom structures. Nevertheless, a critical role for in vivo conformational transitions between soluble helical and forms is suggested, although direct observation of these conformational transitions is difficult due to A peptides poor tendency to dissolve in water. For this reason, detailed structural studies are normally performed in mixtures of water and organic fluorinated solvents, such as trifluoroethanol (TFE) or hexafluoroisopropanol (HFIP), and micellar solutions [14] . In these media, A peptides are not aggregated and have predominantly -helical conformations. Mixtures of water and TFE can also induce structure. This property was exploited by Tommaselli and co-workers [15] in order to characterize the conformational transitions of A peptides from helical to forms. With an integrated approach of experimental (NMR and CD) and theoretical methods (MD simulations), they demonstrated that the 25-35 core sequence is a key motif in the -to-conformational transition. The conformation is stable in solutions containing 90-99% of water, and addition of appropriate amounts of HFIP turns the peptide conformation from to . Currently, attempts to identify peptide regions driving conformational transitions induced by the surrounding medium, represent a possible approach to understand the molecular basis of AD. In addition, the structural characterization of a partially folded intermediate in the -to-transition and vice versa could allow the rational design of molecules able to interfere with the aggregation process.
The structure of the oligomeric species is not known in detail until now. Recently, a specific A oligomer has been described, a dodecamer able to bind specifically to the dendritic processes of the neuron and block the membrane potentiation [16, 17] . From the structural point of view, the oligomer appears to be as a micelle of A -peptides with the hydrophobic C-terminus hidden in the micelle center and a critical 17.6 mM micellar concentration [18] . The peptides in the oligomer are mainly unstructured [19] . In 2005, Laurents et al. proposed a different kind of A aggregated forms, the so-called -balls, detected at pH lower than 4 [20] .
The product of small oligomers aggregation is the A protofibril. It has a rod-like structure with a length of nm, characterized by a core with a high -sheet content, as suggested by its resistance to hydrogen exchange and its capacity to bind Congo Red and Thioflavin T. Protofibrils can elongate by association of smaller protofibrils with a speed depending on A concentration, pH, ionic strength and temperature. They can rapidly convert in A fibrils, when in presence of little preformed fibrils, even though they seem to be in a prevalent dynamic equilibrium with lower-order oligomers [21] .
The final step in the A aggregation pathway is protofibril maturation into fibrils. This process may be driven through hydrophobic contact between 3 and 6 protofibrils that are supposed to form a fibril. A fibrils are composed of multiple protofibrils twisted around each other, resulting in filamentous structures with a diameter of 6-10 nm. A fibrils are constituted by two or three protofibrils arranged to a left-handed superhelix forming an S-shaped fibril cross section. Amyloid fibrils have been defined as thermodynamically stable, structurally organized, highly insoluble, filamentous protein aggregates being composed of repeating units of -sheets aligned perpendicular to the fibre axis, with potentially both parallel and antiparallel organization. In the amyloid fibrils, this -sheet structure is limited in an arrangement in which the individual -strands run transversely to the main fibril axis. This structure is termed the crossconformation.
The determination of the full molecular structures of amyloid fibrils requires specific experimental approaches [ 22, 23] , due to their noncrystalline, insoluble nature. While monomeric peptides present prevalently a random coil structure, for amyloid fibrils the predominant secondary structural elements are -strands. The study of secondary structure in amyloid fibrils therefore consists on the identification ofstrand and non--strand segments (i.e., turns, loops, or bends [31] . The experimental determination of quaternary structure in amyloid fibrils has been relatively difficult. The last models for amyloid fibrils structures support the idea that its core contains two or more layers of -sheets. The quaternary structure is generated by a specific set of contacts among amino acid side chains that project from adjacent -sheets. In fibrils formed by relatively long peptides, the adjacent -sheets may be formed either by -strands from the same or from different peptide molecules, indicating that the side chain contacts from which quaternary structure takes origin can be either intramolecular or intermolecular.
INTERACTION WITH LIGANDS
The structural features of the interaction of ligands with A are mainly unknown, even if a great number of different molecules that interact with A peptides have been proposed. There are some sporadic exceptions among these compounds. Three significant cases are reported. The first example concerns the interaction of A with cyclodextrins, torus-shaped rings built up by different numbers of glucose residues. As firstly reported by Qin et al. [32] , -cyclodextrin interacts with the A -peptide and the interaction is suggested to inhibit the formation of the soluble oligomers with an IC 50 of 5mM, as determined with scintillation proximity assay [33] . Camilleri et al. demonstrated by mass-spectrometry that the stoichiometry of the A -peptide and -cyclodextrin is 1:1 [34] . The main interaction with amino acid residues has been suggested to involve the aromatic rings of phenylalanines and the hydrophobic cavity of cyclodextrin. In 2004, Danielsson and co-workers characterized the interaction between A -peptide and -cyclodextrin by NMR [35] . The A -peptide has four putative aromatic binding sites, F4, Y10, F19 and F20. They demonstrated that if the phenylalanines at positions 19 and 20 in the fragment A 12-28 are replaced with glycines, thus removing all aromatic side chains, no interaction occurs. This shows that the phenylalanines are necessary for -cyclodextrin-peptide interaction. For the central fragment A 12-28 where the phenylalanines are present, interaction occurs and K d = 3.8 mM. Induced chemical shift changes suggested that the interaction mainly involves phenylalanine 19. This binding is not strong, but it is in agreement with the fibril reducing activity of -cyclodextrin determined earlier. In the case of cyclodextrin determined earlier. In the case of the full-length peptide, the combined results from induced chemical shift changes and diffusion data were consistent with a two-site binding involving F19 and Y10 with a total apparent dissociation constant of K d = 4 mM. The individual K d for the two sites was determined to be K d F = 4.7 mM and K d Y = 6.6 mM, respectively, if the sites are assumed to be independent. The outermost N-terminal aromatic amino acid F4 did not seem to bind -cyclodextrin with any measurable affinity. This was tested by showing that the fragment A 1-9 does not bind -cyclodextrin. Other types of cyclodextrins were studied and showed no binding. This may be due to the hydrophobic pocket of -cyclodextrin that has optimal dimensions for interaction with the aromatic side chains. The -andcyclodextrins have too small or too large cavities for interaction to take place.
The second example concerns the study of the interaction between gangliosides and A 1-40 peptide. This interaction was characterized in 2004 by Mandal et al. [36] in a membrane-mimicking environment, dissolving asialo-GM1 and ganglioside GT1b in a SDS (sodium dodecyl sulphate) solution. As previously reported [37] , A peptides associate with gangliosides in Alzheimer's brains and form specific complexes with gangliosides in vitro. Different experimental evidences show that ganglioside binding induces A peptide oligomerization [38] . From the structural point of view, gangliosides are sialic acid-containing glycosphingolipids and consist of two main components: a hydrophobic ceramide unit, which anchors the gangliosides to the plasma membrane, and a hydrophilic oligosaccharide chain, to which one or more sialic acid units (N-acetylneuraminic acid) are attached. Gangliosides are abundant components of neuronal membranes and are involved in important neurobiological events such as neurodifferentiation, synaptogenesis, and synaptic transmission. Asialo-GM1 and GT1b ganglioside have four sugar moieties in common; however, GT1b has three additional sialic acids compared to asialoGM1 that does not contain sialic acid units. Asialo-GM1 and GT1b ganglioside binding to A 1-40 peptide were analyzed by heteronuclear NMR spectroscopy. Experimental data showed that, while GT1b is unable to bind A , asialo-GM1 addition induces appreciable chemical shift variations in A 1-40 amide protons. In particular, asialo-GM1 docks between region I (E3-V24) and region II (G29-V40) of A . These evidences explain why GM1 does not bind the shorter A 1-28 peptide [38a]. In fact, in the case of A 1-28, the absence of the main binding region G29-V40 would prevent GM1 binding. In addition, Matsuzaky and co-workers [39a] showed that gangliosides follow the order GT1b > GD1a > GD1b > GM1 to induce -sheet formation. These NMR data are in agreement with previous reports, suggesting that when the size of the ganglioside headgroup increases with the number of sialic acids (GT1b > GD1a > GD1b > GM1), it becomes difficult to accommodate the bulky saccharides between regions I and II of A and -sheet formation proceeds. The interaction of A peptide with the ganglioside GM1 is also currently under study by Bruix and co-workers [40] . It is worth noting that opposite results were obtained by Ariga et al. using a membrane-mimicking system composed of dipalmitoylphosphatidylcholine, where A had lower affinity for asialoGM1 than for gangliosides with several sialic acids [39b].
SMALL MOLECULE LIGANDS THAT INTERACT WITH A
Based on the conformation/oligomerization hypothesis, molecules able to stabilize the soluble A (sA ) conformation, to destabilize the altered amyloidogenic conformer, and to prevent the required conformational transition could be effective inhibitors of amyloid plaque formation and very potent drug candidates for AD treatment.
Peptides
The intrinsic affinity of A for itself suggested that Aspecific interactions could be the basis for the development of compounds binding to A and preventing its polymerization. It has been claimed that fibrillogenesis can be inhibited by short synthetic peptides partially homologous to A . Several elegant strategies have been used to design peptidic inhibitors of A aggregation. Many of these approaches rely on using fragments of the parent A sequence as recognition elements in a dominant negative fashion. Typically, fibrildisrupting chemical elements are incorporated into A derived peptides in the form of N-or C-terminal modifications, conformationally constrained amino acids, or modifications to the peptide backbone. These concepts have also been applied to D-amino acid variants of the parent A sequence. Given the hypothesis that aggregation intermediates are responsible for A toxicity, one approach to contrast this problem is to identify the regions of A that are at the basis of the polymerization into amyloid fibrils. Gazit et al. [41] . analyzed a variety of short functional fragments from unrelated amyloid-forming proteins and observed a remarkable occurrence of aromatic residues. They speculated that aromatic residues raise the possibility that -stacking may play an important role in the molecular recognition and selfassembly process that lead to amyloid formation.
In A the aromatic residues are the two phenylalanine residues in position 19 and 20. In particular, the short fragment of A QKLVFF was shown to bind specifically to fulllength peptide [42] . Other studies have shown that not only QKLVFF, but also LVFFA and its derivatives [43] and LPFFD [44] , are all potent inhibitors of amyloid formation from A polypeptide. Another recent study demonstrated that the seven amino acid A fragment, KLVFFAE, forms well-ordered amyloid fibrils [24a]. These findings point to the pair of phenylalanine residues as the major structural element that mediates binding of the QKLVFF peptide to the A polypeptide. As the formation of amyloid fibrils is a process of molecular recognition and self-assembly, the high affinity and selectivity of the FF motif seems to provide the molecular recognition element needed for such process in the context of the full-length A . These candidate binding compounds could theoretically prevent all aggregation, or even cause further association of toxic oligomers into larger nontoxic aggregates. Cairo and co-workers [45] proposed inhibitors designed as containing both the ''recognition domain'' (LVFF or KLVFF) and a ''disrupting domain'', a polypeptide chain with the ability to interfere with A aggregation. A series of variant of the KLVFF sequence were synthesized. Truncation of the C-terminal phenylalanine reduced the affinity by approximately 10-fold. The D-amino acid sequence KLVFF binds with similar affinity to the Lamino acid sequence, as reported by Chalifour et al. [46] . Substitution of tyrosine at either the 19 or 20 position did not alter the affinity; however, replacement of both phenylalanine residues with tyrosine was detrimental. Substitution with histidine in position 19, but not in position 20, led to a substantial loss of binding; nevertheless, a double histidine substitution partially restored binding. Substitution of phenylalanine with tryptophan residues gave mixed results. Murphy et al. focused their attention also on the "disrupting domain"; they demonstrated that KLVFF sequence that also possess positively charged residues at the C-terminus bind with higher affinities than does KLVFF alone. Among these peptides, KLVFFK 4 (K d = 37 μM) and KLVFFK 6 (K d = 40 μM) were the most potent in preventing A -associated toxicity. These results suggested that a peptide domain lacking direct homology with A can play a significant role in binding. The increased affinities of sequences bearing lysine residues are not due to nonspecific Coulombic interactions of the peptides with the A -fibrils surfaces; in fact, there was a lack of affinity when three lysine residues were substituted with glutamic acid residues (four different isomers). These substitutions were useful to speculate that the position of the positively charged residues has a critical influence on A affinity. Placement of the positively charged residues close to position 20 gives rise to the most potent ligand of the four isomers. Placing the lysines three residues apart from the region of residues 16-20 with intervening negatively charged residues reduces the affinity by 14-fold. Placement of positive charge at the N-terminus of the sequence of residues 16-20 results in an activity that is lower than that of compounds with a modification at C-terminus. Argininecontaining compounds were tested to determine the potency of compounds that incorporate positively charged residues other than lysine. These compounds possess activity similar to that with lysine. Another example of peptide inhibitors containing the A amino acid sequence 16-20 was presented by Austen et al. [47] ; they designed two peptides with RG-/-GR residues added at the N-and C-terminal ends of KLVFF to aid solubility, in particular the two molecules are RGKLVFFGR and RGKLVFFGR-NH 2 . On the basis of Th-T results and TEM micrographs, both peptides inhibited the formation of A late aggregates, but the results for the inhibition of the oligomerization revealed that the second one had the best inhibitory effect, with the first one having a slight blocking effect at higher concentrations. It is likely that the second one inhibits oligomeric formation by binding to the monomeric A molecule, thereby blocking the formation of early soluble aggregates, as shown by size exclusion chromatography and oligomeric specific ELISA. Interestingly, only RGKLVFF-NH 2 , which completely inhibited the early aggregates of A , was able to protect cells from A toxicity. However, in the case of the first peptide, which showed only inhibition of the late aggregates of A , no neuroprotective effects were demonstrated. The results reported by Austen and co-workers provide clear evidence that the neuroprotective effects were due to the inhibition of formation of early aggregates rather than late aggregates of A . The above studies are quite significant as they suggest new approaches for the interference with A assembly and peptides that may be the lead compounds for the development of molecules preventing A aggregation in vivo. The use of multiple simultaneous interactions to enhance the affinity and specificity of binding, known as multivalency, is an important concept in biology. In the past, different types of scaffold molecules have been used to obtain multivalent structure, such as colloidal gold particles and poly(ethyleneglycol) (PEG). These approaches have some disadvantage, in particular the large size of the particles (PEG) and the lack of control over the number of peptides attached (colloidal gold). These disadvantages are overcome using dendrimers, multivalent macromolecules with regular, highly branched, structures and dimensions resembling those of small proteins. Starting from previous informations, Chafekar and co-workers [48] synthesized a first generation KLVFF dendrimer (K4 -four KLVFF on one scaffold) by using native chemical ligation and investigated the effect of dendritic KLVFF on the aggregation of A (1-42) as well as its effects on preformed aggregates. Their data show that the linkage of KLVFF to a dendrimeric scaffold potentiates its inhibitory effect on A aggregation and on the disassembly of pre-existing aggregates; in fact they used 20-fold lower concentration of K4 (per peptide subunit) to obtain a similar inhibition as KLVFF. Previously, a branched hexameric PEG linked to inverse FFVLK [49] sequence was shown to increase the potency of A inhibition, but also in this case the K4 conjugate from the study of Chafekar et al. gave stronger multivalent effect.
Looking at the A (1-42) sequence, Fülop et al. [50] proposed another inhibitor with a structure analogue to the sequence 31-35, which plays important roles in A aggregation [51] . Other types of peptides containing residues acting as -sheet breaker were proposed. In particular Soto and coworkers [44] proposed a -sheet breaker peptide iA 5 (LPFFD), designed from the central hydrophobic region of A . A proline residue was added into the sequence to disrupt -sheet formation, as incorporation of this amino acid within a -pleated structure is highly unfavourable; an aspartic acid charged residue was added at the end of the peptide to increase solubility. It was demonstrated that iA 5 inhibits in a dose-dependent manner fibrillogenesis of either A (1-40) or A (1-42), disassembles preformed fibrils in vitro and prevents neuronal death induced by fibrils in cell culture. In addition, the peptide significantly reduced amyloid -protein deposition in vivo and completely blocked the formation of amyloid fibrils in a rat brain model of amyloidosis. Looking at these results, they hypothesized that -sheet breaker peptides probably inhibit amyloid formation by binding to monomeric/dimeric A peptides, thereby blocking the formation of the oligomeric -sheet-conformation precursor of the fibrils.
Etienne and co-workers [52] proposed peptides which contain , -disubstituited amino acid ( AA) in the hydrophobic core of A (Fig. 2) ; in particular they utilized an alternating AA/L-amino acid design to obtain a peptide that interacts with A by hydrogen bonding as well as by side-chain interactions. The AAs having side-chain larger than methyl stabilized extended peptide conformations.
The common feature of -sheet structure in amyloid fibrils, formed by proteins that are otherwise structurally diverse, suggests that peptide backbone hydrogen bonding may be important in the assembly and stability of amyloid fibrils. Based on this idea, another interesting approach in this area of A mimetics is the substitution of alternating amide hydrogens with methyl groups. This approach may be useful to prevent the -sheet propagation necessary for A fibrillization. Furthermore, these N-methylated peptides are more hydrophobic than the unmodified ones, have the possibility for increased blood-brain barrier penetration, resistance to proteolytic degradation and tend to prevent self aggregation. Gordon et al. [53] designed inhibitors based on KLVFF motif, containing N-methylated amino acids, in particular K NMe LV NMe FF NMe AE (Fig. 3) was the most potent in vitro inhibitor among the peptides tested. N-methylated derivatives, based on A (25-35) sequence GSNKGAIIGLM, have also been reported by Hughes et al. [54] . They demonstrated that N-methylated derivatives of the A sequence can prevent the aggregation and inhibit the resulting toxicity of the wild type peptide. N-methylation is known to promotesheet formation by locking the residue into a conformation and has been shown to generate soluble monomeric -sheet peptides. By N-methylating the amide NH groups at the outer edges of the -sheet and so prevent intermolecular hydrogen bonding, both aggregation and toxicity should be prevented. Because the NMe derivatives are homologous to -(25-35), they are expected to bind to the peptide but to prevent the further addition of -(25-35) monomers. It was shown that these derivatives, which taken individually are soluble and non-toxic, can prevent the aggregation and inhibit the toxicity of the wild type peptide. All the Nmethylated peptides had varying effects on prefolded fibrils and fibril assembly even if the N-methylated glycine peptide(25), had properties similar to the wild type. In particular, A (25-35) with N-methylated glycine(33) was shown to completely inhibit fibril formation, disassemble preformed fibrils, and reduce cellular toxicity. Another peptide with the methylation on the leucine(34) was able to alter the fibril morphology and to reduce the wild peptide toxicity. These results would imply that the position of N-methylation is crucial for efficacy and is linked to a critical region of the growing amyloid fibril. Gordon and co-workers [55] investigated also the effect of replacing the hydrogen bond donating amide NH backbone with ester bond surrogates at alternating positions, to prevent the hydrogen bonding of the amyloidogenic peptide and to reduce the aggregation. In addition, the ester carbonyl is less basic than the amide carbonyl and, as a consequence, is a weaker hydrogen bond acceptor. At the same time, the ester bond shares many structural similarities with the amide bond, such as a predominance of the trans conformation and similar bond lengths and angles. Based on this information, they hypothesized that the substitutions would yield peptides with effective fibrillogenesis inhibitor activity and would permit a more direct assessment of the role of hydrogen bonds in stabilizing amyloid fibrils. The synthesized peptides presented two hydrogen bonding faces when arrayed in an extended -strand conformation; one face had normal hydrogen bonding capabilities, but the other face was missing amide protons and its ability to hydrogen bond was severely limited.
Thus, the incorporation of ester bonds constitutes a more conservative substitution for peptide bonds than the incorporation of N-methyl amino acids. The incorporation of two ester bonds at alternate residues of the A (16) (17) (18) (19) (20) (16) (17) (18) (19) (20) N-methylated also suggest that interfering with hydrogen bonding is sufficient to prevent A (1-40) fibrillogenesis and that steric contributions from the Nmethyl group are not required. What is also very interesting is the reported disassembly of pre-existing fibers, which may suggest that many of these peptides can bind at the end of the fibrils and possibly serve to influence the thermodynamic equilibrium between oligomers and fibrils. Thus, it is clear that the considerable efforts in the rational design of Atargeting molecules based on the parent A sequence have been quite fruitful in providing a large class of compounds with different activity. These peptidomimetic molecules provide a class of compounds that may help to elucidate the mechanism of amyloid aggregation, perhaps by trapping intermediates, as well as providing inroads into the design of diagnostic and therapeutic reagents.
Non-Peptidic Small Molecules
Some non-peptidic small molecules are able not only to inhibit the formation and extension of -amyloid fibrils (fA ), but also to destabilize fA in vitro. These include naturally occurring or commercially available bioactive compounds, drugs, surfactants [56] , Cu/Zn chelators [57] , phenothiazines [58] and sulfonated dyes such as or Congo red (CR) (Fig. 4) and its derivatives [59] . Among them CR was the first small molecule reported to bind to amyloid in tissue sections, exhibiting the characteristic yellow-green birefringence under cross polarized light. Later thioflavin T (ThT) (Fig. 4) and thioflavin S (ThS) were also shown to stain amyloid deposits. These two dyes are the classical reagents to detect characteristic -sheet mediated fibrillization. [61] have also been shown to inhibit fibril formation at higher concentrations. Not surprisingly perhaps, many reported small molecule inhibitors are similar to CR and ThT, in that they are planar and aromatic. According to Porat et al. [62] , who reviewed the possible mode of interaction with A , small molecules with aromatic moieties can intercalate within grooves created by -sheets in both the soluble oligomeric forms as well as in the large fibrils. From this first study, several different types of molecules were found to be active in the inhibition of fA aggregation, with a wide range of activity, from less than 100 nM to more than 100 μM. In the table presented below, we resume the IC 50 (Fig. 5) , that has two orthodihydroxyphenyl rings symmetrically bound by a short carbohydrate chain, the most effective molecule. The activity of NDGA could be ascribed to its compact and symmetric structure that might be suitable to specifically bind free A , thus inhibiting the polymerization of A into fA [76b]. Alternatively, this structure might be suitable for specific binding to fA and subsequent destabilization of the -sheet conformation of A rich in fA molecules.
CR [60] and ThT
Li et al. [78] reported that dopamine and L-DOPA were able to inhibit the formation of amyloid fibrils in a solution 1 mg/mL of A , in a range from 10 to 100 μM.
Other molecules that present a very high activity against amyloid fibrils and plaque formation are red wine and green tea related polyphenols [62] ; these compounds were also analyzed by Ono et al. [79] , during their systematic work. The wine-related polyphenols inhibit fA formation from A (1-40) and A (1-42) as well as destabilized preformed fA and fA (1-42) dose-dependently in vitro. Within this class of compounds tannic acid showed the best activity.
Tannic acid (TA), a commercial form of tannin, is a polymeric polyphenol with a weak acidity (pK a around 10) due to its phenol groups. Its structure is based mainly on glucose esters of gallic acid. It is a yellow to light brown amorphous powder which is highly soluble in water. Ono et al. examined the effects of TA on the formation and extension of fA and fA , as well as on the destabilization of fA s at pH 7.5 at 37 °C in vitro, using fluorescence spectroscopy with ThT, Congo Red and electron microscopy [68] . They also compared the activity of TA with the antiamyloidogenic and fibril destabilizing effects of Myricetin (Myr) (Fig. 6) , RIF, Tetracycline (TC) and NDGA. TA exhibited potent anti-amyloidogenic and fibril-destabilizing effects and the EC 50 for the formation or extension of fA s or for the destabilization of fA s were in the order of 0.012-0.065 μM for both A (1-40) and A (1-42). They suggested that the anti-amyloidogenic and fibril-destabilizing activity of NDGA and wine-related polyphenols may be classified in the following order: TA > NDGA = Myr = morin = quercetin > kaempferol > (+)-catechin = (-)-epicatechin > TC. Interestingly, TA, wine-related polyphenols, NDGA, RIF all possess antioxidant activity. Tomiyama et al. [80] . suggested that RIF binds to A by hydrophobic interactions between its lipophilic ansa chain and the hydrophobic region of A , thus blocking the association between A molecules that lead to fA formation. The anti-amyloidogenic activity of TCs, and of small molecule anionic sulfonates or sulfates is also related to the propensity to bind to A [77, 81] .
Another important A -ligand is curcumin (diferulomethane), a low molecular weight molecule with potent antioxidant and anti-inflammatory activities that has a favorable toxicity profile and is also under development as a potential cancer chemotherapeutic agent. Curcumin (Cur) (Fig. 6) is a major component of the yellow curry spice turmeric. This spice is used in the traditional diet and as an herbal medicine in India [82] . The frequency of Alzheimer's disease in India is roughly one-quarter of that in the US (e.g., 0.7 vs. 3.1% between 70 and 79 year) [83] . Maybe not by chance Cur is a free radical scavenger [84] , protecting the brain from lipid peroxidation [73a] , and scavenges nitric oxide-based 1 μM) . Later, other authors [62, 63, 70b] reported lower IC 50 . The effects of Cur did not depend on A sequence but on fibril-related conformation. Brain sections of Tg2576 mice with Alzheimer's disease were incubated with Cur and revealed preferential labeling of amyloid plaques. In vivo studies showed that Cur injected peripherally into aged Tg mice crossed the bloodbrain barrier and bound A plaques. When fed to aged Tg2576 mice with advanced amyloid accumulation, Cur labeled plaques and reduced amyloid levels and plaque burden. Hence, Cur directly binds small -amyloid species thus blocking aggregation and fibril formation both in vitro and in vivo. These data suggested that low dose Cur effectively is able to disaggregate A as well as to prevent fibril and oligomer formation, supporting the rationale for Cur use in clinical trials preventing or treating AD. In 2007, Reinke et al. [85] studied the structure-activity relationships of amyloid -aggregation inhibitors based on Cur. They studied the effect of three prominent features on inhibition of amyloid aggregation: the presence of two aromatic end groups, the substitution pattern of these aromatics, and the length and flexibility of the linker region. They found that modification of any one of the modules has profound effects on activity.
To establish the contribution of each structural module to the activity, they assembled a collection of curcumin related compounds. Cur is composed of two relatively polar aromatic groups connected by a rigid linker. Reinke et al., in their first experiments investigated whether both aromatic groups were required for activity using the ThT assay. They found that simple compounds with a single aromatic group, like vanillin, salicylic acid or ferulic acid, did not decrease aggregation of 25 μM A (1-42), even at high concentrations (500 μM). They also studied the relation between the substituent on the two phenyl group and the activity, observing that the aromatic end groups require one or more polar, hydrogen bonding substitutions for optimal inhibition of A aggregation.
In Cur, CR, and Chrysamine G (CG) (Fig. 7) the distances between the terminal aromatic regions are all strikingly similar, it was hypothesized that the length of the linker would be important for activity.
Reinkle et al. noticed that length and flexibility of the linker region are not independent variables and established that the optimal are rigid (less than two freely rotating carbons) and restricted between 8 and 16 Å. Interestingly, many of the best amyloid ligands fall within the observed optimal range. For example, CR, CG, NDGA, Cur (Fig. 8) and rosmarinic acid all meet these requirements. In addition, the linker requirement seems to be one of the most significant features, as compounds that fulfill the other substructural requirements, such as the aromatic substitution, still fail to inhibit if they have a short linker. An interesting exception to this observation is resveratrol. Despite its short linker length, this compound is active, suggesting a possible alternative mechanism for inhibition or a possible different different binding site on the amyloid peptide, such as the site occupied by ThT.
Overall, the anti-amyloidogenic molecules can be classified into four group based on the activity. Dopamine and tannic acid were classified into the strongest antiamyloidogenic group, compound like NDGA, Cur, rosmarinic acid or myricetin into the second group, L-DOPA orcarotene into the third group, RIF and TC into the fourth group. Poly(vinylsulfonic acid, sodium salt), 1, 3-propanedisulfonic acid, disodium salt, -sheet breaker peptide and nicotine exhibited anti-amyloidogenic activity in a μM range. Fig. (7) . Structure of Chrysamine G. 
CROSSING THE BLOOD BRAIN BARRIER (BBB)
An endothelial cell monolayer associated with pericytes and astrocytes, known as the blood brain barrier (BBB), separates the blood from the cerebral parenchyma; it is characterized by tight intracellular junctions and by the absence of fenestrations [86] . The BBB is the homeostatic defense mechanism against pathogens and toxins. Complex and highly regulated, the BBB screens the biochemical, physicochemical and structural features of solutes at its periphery, thus affording barrier selectivity in the passage of desired molecules into the brain parenchyma. The BBB provides the brain with nutrients, prevents the introduction of harmful blood-borne substances, and restricts the movement of ions and fluid to ensure an optimal environment for brain function. It protects the brain from substances which are neurotoxic in physiological concentrations. As a consequence of its barrier properties, the BBB also prevents the movement of drugs from the blood into the brain, and therefore acts as an obstacle for the systemic delivery of neurotherapeutics. The BBB determines whether or not a given drug, unless lipid-soluble, small (< 600 Da), electrically neutral and weakly basic molecules, can reach the central nervous system (CNS), either by passive diffusion or through carrier or receptor systems [87] limiting the brain penetration. Furthermore, efflux transport systems may target the drugs that meet these criteria and export them from the brain. As a result, the BBB excludes many small-molecule pharmaceuticals, and nearly all biopharmaceuticals such as genes and proteins fail to penetrate into the brain tissue to an appreciable extent [88] . Thus, although the surface area of the human brain microvasculature available for drug transport (~ 20 m 2 ) is more than adequate for treating the entire brain volume, the barrier properties of the BBB continue to restrict brain drug delivery via the bloodstream [89] .
There is growing evidence for BBB damage in AD [90] . Most A plaques are located in the proximity, or are directly in contact with cerebral capillaries. Alterations of the expression and distribution of the A transporters and tight junction proteins have been observed at the level of endothelial basement membrane of cerebral microvasculature, where the efflux of A from brain is regulated. These observation open the possibility of potential therapeutic alternatives of AD based on sealing a compromised BBB and reversing AA deposition.
CEREBRAL CLEARANCE OF A ACROSS THE BBB
The amyloid hypothesis states that a variety of neurotoxic A species contribute to the pathogenesis of Alzheimer's disease. Accordingly, a key determinant of disease onset and progression is the appropriate balance between A production and catabolism. It has been suggested that insufficient clearance of A may account for elevated A levels in the brain and the accumulation of pathogenic amyloid deposits in sporadic AD [89] . Ito et al. demonstrated that the efflux clearance of [ 125 I]A in rats to be 11.0 μL/(min g brain) [91] . Experimental evidence suggests that brain and blood A are in equilibrium, through the BBB, and that peripheral sequestration of A may shift this equilibrium towards the blood, eventually drawing out its excess from the brain ("sink" effect) [92] , reducing A -related pathology and dysfunction [93] . Clearance seems to be accomplished via two major pathways: proteolytic degradation and receptor-mediated transport from the brain.
Proteolytic Degradation
A number of proteases have been implicated in the proteolytic clearance of A from the CNS, the two major endopeptidases involved in A degradation are zinc metalloendopeptidases, referred to as insulin degrading enzyme (IDE) or insulysin, neprilysin (NEP), endothelin converting enzyme, and plasmin [94] .
Receptor-Mediated Transport
Clearance is achieved by the brain-to-blood efflux transport system across the BBB. Increasing evidence suggests that the low-density lipoprotein receptor-related protein (LRP) and the receptor for advanced glycation end products (RAGE) are involved in receptor-mediated flux of A across the BBB [95] . While LRP appears to mediate the efflux of A from the brain to the periphery, RAGE has been strongly implicated in A influx back into the CNS. Therapeutic strategies therefore can be aimed at upregulation of LRP-1 or downregulation of RAGE.
ApoE, acting to traffic lipids throughout the brain, plays critical roles in regulating brain A peptide levels, as well as their deposition and clearance [96] . Recently, Jiang Q. et al demonstrated that lipidated forms of ApoE act to enhance the clearance of A peptides from the brain, facilitating the proteolytic degradation of A . They demonstrated that elevation of lipidated forms of ApoE results in reduced A peptide and plaques levels in an animal model of AD [97] .
The molecular pathways responsible for efflux and influx of A across the BBB suggest an array of potential therapeutic strategies that could be aimed at reducing the accumulation of cerebral A . The A clearance should preferably be performed before the proteins cluster into the toxic oligomers and can be achieved in many ways: 1) immunotherapy; 2) enzymatic degradation by metallo-endoproteases; 3) stimulating clearance by increasing transport over BBB by stimulating the LRP receptor or inhibiting RAGE (or P-gp). Most recently, immunological approaches have been implemented to reduce A load in the CNS. Recent studies have demonstrated that beta amyloid burden in transgenic animal models can be either peripheral or cerebral infusion of exogenous anti-A antibodies (passive immunization) or by immunization with synthetic A peptide. Two basic mechanisms have been proposed to account for the findings of reduced amyloid load in transgenic animals with high anti-A antibody titers. First, anti-A antibodies may cross the BBB and bind to A in the brain, prompting digestion by activated microglia. Alternatively, antibodies or agents that have high affinity for A (ganglioside GM1 or gelsolin) may bind and sequester A in the periphery and either promote efflux from or inhibit influx back into brain [92, 98] .
Another possibility to enhance the A clearance from the brain is the upregulation of A degradating enzymes, for example NEP activity can be upregulated by the administration of somatostatin [98] .
CURRENT AND NOVEL THERAPEUTIC APPROACHES FOR THE TREATMENT OF ALZHEI-MER'S DISEASE
Goals of pharmacologic therapy for AD are to stabilize and modulate the expected decline of cognitive, functional and behavioral symptoms [114] . Available treatments are not intended to alter the progressive pathophysiology of the disease, but rather are considered to be symptomatic therapies. Presently, cholinesterase inhibitors (ChEIs) are the first-line medications in the treatment of AD and are effective in delaying cognitive impairment. Management of noncognitive psychiatric symptoms require additional adjunctive medications, such as antipsychotics, antidepressants, and anxiolytics [115] . Alternate treatments using nonsteroidal antiinflammatory drugs (NSAIDs), Gingko biloba, and hormone replacement therapy have been used with varying success in the treatment of AD. Newer anti-amyloid medications in various stages of clinical trials show promise in modifying the disease process. Glutamate-mediated toxicity in the cerebral cortex also has been hypothesized to contribute to the neurodegeneration of AD. In 2003, the FDA approved memantine, a low to moderate-affinity noncompetitive Nmethyl-D-aspartate receptor antagonist, for the treatment of moderate to severe AD [116] . In patients with moderate to severe AD receiving a stable dose of memantine results in significant improvement in cognitive, functional, and global outcomes compared with placebo. Gingko extract has been used for thousands of years in traditional Chinese medicines for a variety of conditions. Recently, it has become more widely used in the United States to treat age-related physical and cognitive disorders [115] . The efficacy of gingko in the treatment of AD has been attributed to the flavonoid component for its antioxidative and antiperoxidative properties and the terpenoid component for its anti-inflammatory effects [117] . Estrogens are neuroprotective against oxidative stress, excitatory neurotoxicity, and ischemia in the brain. Several small short-term randomized clinical trials and some epidemiologic studies have suggested efficacy of hormone therapy in the treatment of mild to moderate AD [118] .
Currently there are four categories of anti-amyloid drugs in clinical trials with promise to modify the AD process: 1) immunotherapies; b) secretase inhibitors; 3) selective Alowering agents; and 4) anti-A aggregation agents. Several anti-aggregation agents, which are in clinical testing, are thought to prevent fibril formation and facilitate A clearance. Tramiprosate, a small glycosaminoglycan (GAG) mimetic, binds to soluble A inhibiting fibril formation, resulting in a decrease of soluble A levels in CSF and reducing amyloid plaque formation. In a 3-month phase II study in subjects with mild to moderate AD, tramiprosate decreased CSF A concentrations from baseline without effect on cognitive function compared with placebo [119] . Colostrinin, a proline-rich peptide, inhibits A aggregation and has demonstrated moderate improvements in cognitive function for mild more than moderate AD. Unfortunately, these effects were not sustained over long term use [120] .
Novel Therapeutical Promises Exploiting NPs
The currently available diagnostic tools does not allow to screen AD at an early stage, and the therapy is often compromised by the difficulty to cross the BBB.
The idea to exploit a sort of "cargo" that allows drugs and diagnostic to cross the BBB is very actractive. To accomplish this task, one must take advantage advantage of one of the molecular transport systems permitting the uptake of nutrients into the brain. One of these transport systems, knows as receptor mediated transcytosis (RMT), employs the vesicular trafficking machinery of the endothelium to transport substrates in the brain. Once a chemical entity able to cross the BBB exploiting RMT is found, the drug can be covalently linked or encapsulated, generating a sort of cargo to cross BBB.
Recently, the emerging field of nanotechnology has generated new promises to solve this problem. Nanoparticles (NPs) ranging in size from 10-1000 nm have several advantages: they present a good physical stability in biological fluids; they can be designed, using a wide range of materials, to control release of encapsulated drugs; NPs formulations can be suitable for either hydrophilic or lipophilic drugs. Moreover , NPs possess high drug-loaded capacities; may offer protection from degrading enzymes to sensitive molecules (e.g. peptides) during transportation, increasing their half-life in the blood stream [122] . Many A ligands described in this review cannot cross the BBB. Conjugation or incorporation into NPs might overcome this problem. The NPs surface can be modified with specific molecules to avoid recognition by the macrophages of the reticuloendothelial system (RES) and for prolonging the NPs blood circulation residence time [123] . Finally, the NPs surface can be modified with specific ligands in order to achieve site-specific drug delivery and successful penetration of the BBB [124] . Many A ligands described in this review cannot cross the BBB. Conjugation or incorporation into NPs might overcome this problem.
Multiple presentation of a single ligand at the surface of NPs will exploit the cluster effect [125] that strongly enhances the adhesion properties. Furthermore, NPs can be functionalized with molecules performing different roles, such as 1) interaction with BBB, 2) stimulation to cross BBB, 3) PET and MRI contrast agents. Such NPs combines the different properties required for diagnosis and therapy.
CONCLUSION
A wide number of small molecules have shown the capacity to prevent A aggregation or even disaggregate A oligomers, fibrils and plaques. The structural features that favour this interaction are becoming more and more clean, We collected these interesting scientific results in this review, that will allow to generate therapeutics and diagnostics for Alzheimer's disease provided that the big problem of transportation through the BBB is solved. 
